Stefanie Schalm is a scientific leader with 15 years of experience in drug discovery, specializing in oncology and monogenic diseases. Currently serving as the Senior Director of Research Oncology at Bayer, Stefanie has successfully led multiple drug discovery programs from target identification to IND submission, including the notable clearance of KT-253. Previously, as a Principal Scientist at Blueprint Medicines, Stefanie contributed to the successful nomination of key targets and the BLU-945 program. Stefanie holds a Ph.D. in Biochemistry from Freie Universität Berlin and is passionate about mentoring and fostering collaboration across diverse teams.
This person is not in the org chart
This person is not in any teams
This person is not in any offices